HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Caspofungin for prophylaxis and treatment of fungal infections in adolescents and adults: a meta-analysis of randomized controlled trials.

AbstractBACKGROUND AND OBJECTIVE:
Caspofungin, a novel echinocandin compound, has been approved for the treatment of esophageal and suspected invasive candidiasis and as salvage therapy for invasive aspergillosis. The aim of this study was to assess the efficacy and safety of caspofungin for the prophylaxis and treatment of fungal infections, compared with other medications.
METHODS:
PubMed, Embase, and the Cochrane Library were searched to identify relevant randomized controlled trials (RCTs) of caspofungin. Nine RCTs were included in this meta-analysis, performed using Review Manager Version 5.0. Analyses of favorable response, microbiological response, mortality rate, survival rate, relapse rate, and adverse events were performed to evaluate caspofungin.
RESULTS:
Caspofungin produced similar effects in favorable response rate [relative risk (RR) = 1.07, 95% confidence interval (CI) 0.98-1.17], microbiological response rate (RR = 1.02, 95%CI 0.90-1.15), mortality rate (RR = 0.98, 95%CI 0.78-1.24), survival rate after 7-day follow-up (RR = 1.00, 95% CI 0.91-1.10), and relapse rate (RR =1.18, 95% CI 0.81-1.73) compared with other antifungal agents in the prophylaxis and treatment of patients with fungal infections, particularly those caused by Candida. There were significant differences in clinical and laboratory adverse events between caspofungin and other antifungal agents in favor of caspofungin (RR = 0.66, 95% CI 0.49-0.89) (RR = 0.66, 95% CI 0.57-0.75).
CONCLUSION:
This meta-analysis shows that caspofungin can be used as effectively as other antifungal agents for prophylaxis and treatment of fungal infections, mainly for Candida, and that it is associated with fewer adverse effects than comparable agents.
AuthorsXin Yuan, Rui Wang, Chang-Qing Bai, Xiu-Jie Song, You-Ning Liu
JournalDie Pharmazie (Pharmazie) Vol. 67 Issue 4 Pg. 267-73 (Apr 2012) ISSN: 0031-7144 [Print] Germany
PMID22570929 (Publication Type: Journal Article, Meta-Analysis, Review)
Chemical References
  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Caspofungin
Topics
  • Adolescent
  • Adult
  • Antifungal Agents (adverse effects, therapeutic use)
  • Caspofungin
  • Data Interpretation, Statistical
  • Echinocandins (adverse effects, therapeutic use)
  • Follow-Up Studies
  • Humans
  • Lipopeptides
  • Mycoses (drug therapy, microbiology, mortality)
  • Randomized Controlled Trials as Topic
  • Recurrence
  • Survival
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: